• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen to attend EANO Congress in Vienna, Austria (15-18 September 2022)

by last | Jun 27, 2022 | 2022, Past Events

Philogen will attend EANO Meeting in Vienna in September 2022. More details on the lecture held by Philogen will follow shortly. Please visit the EANO Meeting Website for additional information.

Philogen to attend Emerging Technologies and Methodologies in Small Molecule Drug Discovery & Synthesis Symposium in Toledo (27-29 September 2022)

by last | Jun 27, 2022 | Past Events

Philogen attends the Small Molecule Drug Discovery & Synthesis Symposium organized by Janssen in September 2022. Prof. Dario Neri, PhD, CEO and CSO of Philogen, to give a presentation entitled “From Encoded Combinatorial Libraries To Targeted Therapeutics” on the...

Philogen to attend Bio Europe in Leipzig (October 24-26, 2022)

by last | Jun 27, 2022 | Past Events

Philogen participates at the BIO-Europe 2022 in Leipzig, the international partnering event in the life science and pharma industry, on October 24-26, 2022. Please meet with us in case you are interested in a collaboration or partnership with the Philogen...

Philogen to attend the Festival of Biologics in Basel (2-4 November 2022)

by last | Jun 27, 2022 | Past Events

Philogen attends the Festival of Biologics in Basel in November 2022. Roberto De Luca, PhD, Head of Antibody Therapeutics at Philogen, to give a presentation entitled “Tripokin: tumor targeted delivery of IL2 potentiated by TNF”. Samuele Cazzamalli, PhD, Head of Small...

Philogen to attend the 10th International Symposium on DNA-Encoded Chemical Libraries in Boston (3-4 November 2022)

by last | Jun 27, 2022 | Past Events

Philogen attends the Symposium on DNA-Encoded Chemical Libraries in November 2022. Prof. Dario Neri, PhD, CEO and CSO of Philogen, to give a presentation entitled “Quantification of DEL selections and implications for good selection protocols” on November 3. Please...
« Older Entries
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch